Comparative study of effect of alpha glucosidase inhibitors-miglitol, acarbose and voglibose on postprandial hyperglycemia and glycosylated hemoglobin in type-2 diabetes mellitus

Abstract

Diabetes mellitus has emerged as a major healthcare problem in India. Management of postprandial plasma glucose (PPG) level is important to prevent the complications associated with type-2 diabetes. Considering paucity of studies motivated us to compare the effect of Acarbose, Miglitol and Voglibose on postprandial hyperglycemia and HbA1C. It was single blind, randomized, parallel group, comparative, prospective clinical trial on 90 diabetes type 2 patients defined as post prandial plasma glucose (PPG) levels more than 200 mg % and glycosylated haemoglobin more than 7 % at visit 1. Glycosylated hemoglobin (p=0.78) and post prandial blood glucose (p=0.61) was reduced more by Voglibose than Miglitol and Acarbose. Though this finding is not statistically significant, adverse effect profile was better with Voglibose (6.66%) than Miglitol (16.66%) and Acarbose(33.33%). Present study recommends use of Voglibose looking at its efficacy and safety profile as preferential choice in the management of postprandial hyperglycaemia in treatment of type-2 diabetes mellitus.